Parke, Davis and Company vs. Doctors' Pharmaceuticals, Inc.

The Court held that under Section 34(d) of Republic Act No. 165, a compulsory license may be granted for a patented invention relating to medicine or necessary for public health and safety once three years have elapsed from the patent's issuance, without requiring the applicant to prove that the patentee failed to work the invention or that the applicant possesses local manufacturing facilities. Because the statutory grounds under Section 34 are disjunctive, establishing that the patented subject matter constitutes medicine independently satisfies the requirement for a compulsory license, and the patentee’s exclusive rights remain expressly conditioned upon the legislative mandate to prevent monopolistic control over public health necessities.

Parke, Davis and Company, a foreign corporation, secured Letters Patent No. 50 on February 9, 1950, covering process and product claims for the chemical compound chloramphenicol, an antibiotic used to treat bacterial infections. In October 1959, respondent Doctors' Pharmaceuticals, Inc. formally requested a voluntary license to manufacture and market medicinal preparations containing chloramphenicol. Upon Parke, Davis’s inquiry regarding operational capabilities, the respondent clarified that it intended only to incorporate the patented compound into finished drug formulations rather than synthesize the raw chemical, citing the statutory three-year period for compulsory licensing. Following the patentee’s refusal, the respondent filed a petition for a compulsory license with the Director of Patents, invoking public health necessity and unmet market demand.

• Parke, Davis and Company owned Letters Patent No. 50, issued on February 9, 1950, covering a process and product claim for the antibiotic chloramphenicol.
• Doctors' Pharmaceuticals, Inc., a domestic corporation, formally requested a voluntary license in October 1959 to produce and market its own brand of medicine containing chloramphenicol.
• Upon Parke, Davis’s inquiry regarding manufacturing capabilities, Doctors' Pharmaceuticals clarified that it did not intend to synthesize the raw compound but sought to incorporate it into finished medicinal preparations, invoking the statutory provision governing patents older than three years.
• After Parke, Davis declined to grant a voluntary license, Doctors' Pharmaceuticals filed a petition for compulsory license with the Director of Patents on March 11, 1960, originally citing four grounds: (1) public health necessity; (2) monopolistic restraint due to refusal to license; (3) inadequate supply and unreasonable pricing; and (4) non-working of the patent on a commercial scale in the Philippines.
• During the administrative hearing on November 14, 1962, the respondent abandoned three grounds and proceeded solely on the assertion that chloramphenicol is a medicine necessary for public health and safety.
• Parke, Davis opposed the application, arguing that the applicant lacked intent and competence to work the patent, that importation alone did not satisfy statutory requirements, that granting the license would harm public interest and local employment, and that the invention was not indispensable to public health.
• The Director of Patents rendered a decision on November 15, 1963, ordering Parke, Davis to grant a compulsory license and directing the parties to negotiate terms within thirty days, failing which he would fix reasonable terms and conditions.

• Petitioner maintained that the Director of Patents gravely abused his discretion by granting a compulsory license without sufficient proof of public health necessity or patent non-working.
• Petitioner argued that Section 34 of Republic Act No. 165 requires the licensee to actually work the patented invention in the Philippines, which the respondent failed to demonstrate, as it merely intended to import the patented compound.
• Petitioner contended that the respondent lacked the technical competence and facilities to manufacture chloramphenicol, and that granting the license would contravene public interest by disrupting local manufacturing, reducing employment, and prejudicing technological development.
• Petitioner asserted that the exclusive patent rights guaranteed under Sections 20 and 21 of Republic Act No. 165 for a term of seventeen years should not be curtailed absent strict compliance with all statutory conditions, and that the Director’s order constituted an improper in personam directive.

• Respondent countered that the patented invention constitutes a medicine, which independently satisfies the condition under Section 34(d) of Republic Act No. 165 for the grant of a compulsory license after three years from issuance.
• Respondent argued that the statutory requirement to "work" the patent does not apply to inventions related to medicine or public health, rendering its intent to import rather than manufacture the raw compound legally immaterial.
• Respondent asserted that it possessed adequate laboratories, technical personnel, and quality-control equipment to safely formulate and distribute chloramphenicol-containing preparations, thereby demonstrating competence to utilize the license.
• Respondent maintained that the compulsory licensing mechanism serves a paramount public interest by preventing patent monopolies, increasing drug availability, and reducing pharmaceutical prices, consistent with the legislative intent behind Republic Act No. 165.

• Procedural Issues: Whether the Director of Patents committed grave abuse of discretion in ordering the grant of a compulsory license without first requiring a formal licensing agreement or conducting a full evaluation of all original petition grounds.
• Substantive Issues: Whether a compulsory license may be granted under Section 34(d) of Republic Act No. 165 for a patented medicine after three years from issuance, notwithstanding the patentee’s objections that the applicant does not intend to manufacture the raw compound, lacks competence to work the patent, or that the grant would contravene public interest and the patentee’s seventeen-year exclusive rights.

• Procedural: The Court found no grave abuse of discretion in the Director of Patents’ issuance of the compulsory license order. The Court held that the Director properly conducted a hearing, evaluated the evidence and memoranda, and exercised adjudicative discretion in ordering the parties to negotiate terms, with the Director retaining authority to fix reasonable terms upon default. The order did not constitute an automatic or arbitrary grant but followed due administrative process.
• Substantive: The Court affirmed the grant of the compulsory license, ruling that Section 34(d) of Republic Act No. 165 operates disjunctively from the other subsections. Because chloramphenicol is a recognized medicine, the three-year lapse from patent grant independently satisfies the statutory condition, without requiring proof of non-working or unmet demand. The Court clarified that the statutory definition of "worked" or "working" in Section 34 does not apply to medicine patents under subsection (d), making the applicant’s intent to import rather than manufacture legally irrelevant. The Court further held that the grant aligns with public interest by dismantling patent monopolies, expanding drug supply, and lowering prices, and that the patentee’s seventeen-year exclusivity is expressly conditioned upon the three-year monopoly period, after which compulsory licensing with reasonable royalties remains statutorily permissible.

• Compulsory Licensing of Patent Inventions Relating to Public Health — The doctrine establishes that patent rights over medicines or inventions necessary for public health and safety are subject to statutory limitations allowing third parties to secure licenses after a fixed period. The Court applied this doctrine to hold that the legislative policy prioritizes public access to essential pharmaceuticals over absolute patent exclusivity, and that compliance with the medicine-related ground alone suffices for license issuance.
• Disjunctive Construction of Statutory Grounds — The Court applied the principle that statutory conditions enumerated with the conjunction "or" are independent and alternative. Because Section 34 of Republic Act No. 165 lists grounds in the disjunctive, establishing any single condition—such as the invention relating to medicine—satisfies the requirement for compulsory licensing without necessitating proof of additional circumstances like non-working or price gouging.

• "The term 'worked' or 'working' as used in this section means the manufacture and sale of a patented article, or the carrying on of a patented process or the use of a patented machine for production, in or by means of a definite and substantial establishment or organization in the Philippines and on a scale which is adequate and reasonable under the circumstances." — The Court cited the statutory definition to clarify that this qualification does not govern medicine patents under Section 34(d), thereby decoupling the compulsory license requirement from local manufacturing mandates.
• "The right to exclude others from the manufacturing, using, or vending an invention relating to food or medicine should be conditioned to allowing any person to manufacture, use, or vend the same after a period of three years from the date of the grant of the letters patent." — The Court adopted this formulation from the Director of Patents to emphasize that patent monopolies on essential health commodities are temporally limited and subject to compulsory licensing to serve the broader public welfare.
• "Compulsory licensing of a patent on food or medicine without regard to the other conditions imposed in Section 34 is not an undue deprivation of proprietary interests over a patent right because the law sees to it that even after three years of complete monopoly something is awarded to the inventor in the form of a bilateral and workable licensing agreement and a reasonable royalty to be agreed upon by the parties and in default of such agreement, the Director of Patents may fix the terms and conditions of the license." — The Court relied on this passage to reject the argument that compulsory licensing constitutes an unconstitutional or statutory violation of the patentee’s exclusive rights, noting that the statutory framework guarantees reasonable compensation.

• Alabama & Ry. Co. v. Odeneal — Cited in support of a flexible, context-dependent definition of the term "necessary," demonstrating that necessity in law admits of degrees and does not require absolute indispensability.
• St. Louis, J & C.R. Co. v. Trustee — Referenced alongside other jurisprudence to illustrate that statutory terms like "necessary" may express convenience, usefulness, or essentiality depending on legislative intent and factual context.
• McCulloch v. Maryland — Invoked to reinforce the interpretive principle that "necessary" frequently imports utility or convenience rather than strict indispensability, supporting the Court’s rejection of the petitioner’s narrow reading of Section 34(d).

• Republic Act No. 165, Section 34 — The controlling provision enumerating the alternative grounds for compulsory licensing, particularly subsection (d) which covers inventions relating to food, medicine, or public health and safety.
• Republic Act No. 165, Section 35 — Cited for the procedural requirement of notice and hearing prior to the grant of a compulsory license.
• Republic Act No. 165, Section 36 — Governs the grant of the license and the Director’s authority to fix terms and conditions upon default, operating as a deed executed by the patentee.
• Republic Act No. 165, Sections 20 & 21 — Referenced to acknowledge the patentee’s general right to a seventeen-year exclusive term, which the Court held is expressly subject to the compulsory licensing exception under Section 34.

• N/A (The decision was rendered en banc with a single unanimous opinion authored by Justice Bautista Angelo; no separate concurring opinions were filed.)